REVIEWS k the members of the ve n w. e TEL-POG 60. B.Pe 93.1707-171419g 13 81. 201) Online links ne in this art ne to ww.nature.com/reviews/drusdisc 2002 Nature Publishing Group © 2002 Nature Publishing Group 502 | JULY 2002 | VOLUME 1 www.nature.com/reviews/drugdisc REVIEWS 57. Blanke, C. D. et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-KIT (CD117). Proc. Am. Soc. Clin. Oncol. 20,1 (2001). 58. Heinrich, M. C. et al. Inhibition of Kit kinase activity: a novel molecular approach to the treatment of Kit-positive malignancies. J. Clin. Oncol. 20, 1692–1703 (2002). An excellent review of KIT as a target for anticancer therapy. 59. Krystal, G. W., Hines, S. & Organ, C. Autocrine growth of small cell lung cancer mediated by co-expression of c-kit and stem cell factor. Cancer Res. 56, 370–376 (1996). 60. Krystal, G. W., Carlson, P. & Litz, J. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrophostins. Cancer Res. 57, 2203–2208 (1997). 61. Krystal, G. W. et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6, 3319–3326 (2000). 62. Wang, W. L. et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer lines by the novel tyrosine kinase inhibitor STI571. Oncogene 19, 3521–3528 (2000). 63. Buchdunger, E. et al. Effects of a selective inhibitor of the Abl tyrosine-kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100–104 (1996). 64. Östman, A. & Heldin, C. H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 80, 1–38 (2001). 65. Nistér, M. et al. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem. 266, 16755–16763 (1991). 66. Kilic, T. et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyridine class. Cancer Res. 60, 5143–5150 (2000). 67. Shimizu, A. et al. The dermatofibrosarcoma protuberans￾associated collagen type 1α/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59, 3719–3723 (1999). 68. Greco, A. et al. Growth inhibitory effect of STI571 on cells transformed by the COL1A/PDGFB rearrangement. Int. J. Cancer 92, 354–360 (2001). 69. Sjöblom, T. et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61, 5778–5783 (2001). 70. Awan, R. A. et al. Patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans (DFSP) may respond to imatinib (STI571, Gleevec). Proc. Am. Soc. Clin. Oncol. 1637 (2002). 71. Jousset, C. et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL–PDGFRβ oncoprotein. EMBO J. 16, 69–82 (1997). 72. Tomasson, M. H. et al. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 93, 1707–1714 (1999). 73. Apperley, J. F. et al. Chronic myeloproliferative diseases with t(5:12) and a PDGFRB fusion gene: complete cytogenetic remission with STI571. Blood 98, 726A (2001). A proof-of-concept study of the efficacy of Glivec in a PDGFR-driven malignancy. 74. Gullberg, D. et al. β1 Integrin-mediated collagen gel contraction is stimulated by PDGF. Exp. Cell Res. 186, 264–272 (1990). 75. Rodt, S. A. et al. A novel physiologic role for platelet-derived growth factor-BB in rat dermis. J. Physiol. (Lond.) 495, 193–200 (1996). 76. Heuchel, R. et al. Platelet-derived growth factor receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3 kinase signaling. Proc. Natl Acad. Sci. USA. 20, 11410–11415 (1999). 77. Jain, R. K. Delivery of molecular medicine to solid tumors. Science 271, 1079–1080 (1996). 78. Pietras, K. et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61, 2929–2934 (2001). 79. Hellström, M. et al. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Exp. Cell Res. 186, 264–272 (1999). 80. Reinmuth, N. et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 15, 1239–1241 (2001). 81. Wang, D. et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 59, 1464–1472 (1999). 82. Buchdunger, E., O’Reilly, T. & Wood, J. Pharmacology of imatinib (STI571). Eur. J. Cancer (in the press). 83. Uehara, H. et al. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice. Proc. Am. Assoc. Cancer Res. 2192 (2001). Acknowledgements We would like to thank the members of the Glivec International Project Team for their crucial contribution to the success of this programme and their kind review of this manuscript: P. Boultbee, V. Buss, S. Dimitrijevic, A. Dortok, D. Filipovic, I. Gathmann, H. Godman, J. Jaffe, L. Letvak, P. Marbach, R. Miranda, J. Ogorka, C. Ogawa, B. Peng, S. Silberman, F. Sutter, S. Szabo, S. Wells and J. M. Ford. We also thank B. Druker for his crucial input and a fruitful collaboration throughout this pro￾gramme, and N. Lydon for his contribution in the early phase of the programme. We thank also C. Schmid for her assistance in editing the manuscript. Online links DATABASES The following terms in this article are linked online to: Cancer.gov: http://www.cancer.gov/cancer_information/ acute lymphoblastic leukaemia | acute myelogenous leukaemia | chronic myelogenous leukaemia | ovarian cancer | prostate cancer | small-cell lung cancer | testicular cancer LocusLink: http://www.ncbi.nlm.nih.gov/LocusLink/ ABL | Abl | AGP | AKT | albumin | ARG kinase | ATP5A1 | ATP5C1| BAK1 | BCL-XL | BCR | Bcr | bFGF | Bruton tyrosine kinase | COL1A1 | CRKL | EGF receptor | c-ERBB2 | ERK1 | ERK2 | FGF | c-FMS | v-fms | IGF-1 receptor | INK4B | insulin receptor | JAK2 | c-KIT | p27 | PDGF-α | PDGF-β | PDGFR-α | PDGFR-β | P-GP | PKC | SCF | v-SRC | STAT5 | TEL | VEGF Medscape DrugInfo: http://promini.medscape.com/drugdb/search.asp cytarabine | Glivec | interferon | taxol | verapamil FURTHER INFORMATION FDA: http://www.fda.gov/default.htm Access to this interactive links box is free online